

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Beri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542

Date: 14th February, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)

Sub: Outcomes of Board Meeting and Un-Audited Financial Results (Standalone) for the Quarter and Nine Months ended 31st December, 2023

Dear Sir/ Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ("Company") in its meeting held today approved the Un-Audited Financial Results (Standalone) for the Quarter and Nine Months ended 31st December, 2023 of the Company as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal.

Further, in Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that Board of Directors of Genomic Valley Biotech Limited at their meeting held today has considered and approved following matters also:

1. Appointment of Mrs. Parul Agrawal (DIN: 01165188) as an Additional Non-Executive (Non-Independent) Director on the Board with effect from 14th February, 2024.
2. Change in Corporate Office of the Company from G-74, Pushkar Enclave, Paschim Vihar, Delhi -110063 to 1st Floor, Space No. 4, Scindia House, Connaught Circus, New Delhi-110001 with immediate effect.

The requisite disclosure as required as per the requirement of Regulation 30 read with Schedule III, Para A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are given as Annexure-A.

The above information will also be available on the Company's Website, www.genomicvalley.com.


The meeting of the Board of Directors commenced on 11:45 A.M. and concluded at 06:30 P.M.

Please take the above on records.

Thanking you.

Yours sincerely

For Genomic Valley Biotech Limited



Anupam Aditya
Company Secretary & Compliance Officer
M. No.: A60613



Annexure-A

Particulars of Appointment of Mrs. Parul Agrawal (DIN: 01165188) as Additional Non-Executive (Non-Independent) Director:

S. No.	Particulars	Details
a)	Name of Person	Mrs. Parul Agrawal
b)	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment as Additional Non-Executive ("Non-Independent Category") Director
c)	Date of appointment / cessation (as applicable)	14 th February, 2024
d)	Terms of Appointment	Subject to approval of the Shareholders of the Company, by means of a special resolution and Liable to retire by rotation [In accordance with the Companies Act, 2013]
e)	Brief profile (in case of appointment)	Mrs. Parul Agrawal is Graduated in Economics (BA Hons) and having experience of 30+ years in Management.
f)	Disclosure of relationships between directors (in case of appointment of a director)	Wife of Mr. Yogesh Agrawal, Chairman and Managing Director of the Company
g)	Declaration	We confirm that Mrs. Parul Agrawal is not debarred from holding the office of Director of the Company, by virtue of any SEBI order or any other such authority.
h)	PAN No.	AAIPA6441M
i)	DIN No.	01165188
j)	Email ID	parulagrwal1970@gmail.com
k)	Mobile No.	9891548915



GENOMIC VALLEY BIOTECH LIMITED
 Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
 TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
 CIN: L01122HR1994PLC033029

Statement of Un-Audited Financial Results for the quarter ended 31/12/2023 and Year to date from 01/04/2023 to 31/12/2023

In Rs.

Sr. No.	Particular	In Rs.					
		3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for previous period ended	Previous year ended
		31-Dec-23 Un-Audited	30-Sep-23 Un-Audited	31-Dec-22 Un-Audited	31-Dec-23 Un-Audited	31-Dec-22 Un-Audited	31-Mar-23 Audited
I	Revenue From Operations	390,000	675,250	6,721,440	1,650,750	17,264,440	27,225,190
II	Other Income	-	-	80,000	15,002	304,877	425,453
III	Total Revenue (I+II)	390,000	675,250	6,801,440	1,665,752	17,569,317	27,650,643
IV	Expenses						
	Cost of materials consumed	-	-	-	-	-	-
	Purchases of Stock-in-Trade	-	-	6,019,200	-	15,836,800	15,836,800
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	-	-
	Employee benefits expense	45,000	90,000	108,000	330,000	1,085,097	1,496,087
	Financial costs	-	-	-	-	-	-
	Depreciation and amortization expense	2,731	2,731	-	8,193	152,648	79,243
	Other expenses	124,702	350,380	252,040	609,748	895,009	1,106,730
	Total Expenses (IV)	172,433	443,111	6,379,240	947,941	17,969,554	18,518,860
V	Profit / (Loss) before exceptional item and tax (III-IV)	217,567	232,139	422,200	717,811	-400,237	9,131,783
VI	Exceptional Item	-	-	8,958,000	-	2,928,212	2,643,164
VII	Profit/loss before Tax (V-VI)	217,567	232,139	-8,535,800	717,811	-3,328,449	6,488,619
VIII	Tax expenses						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-	6,080
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	217,567	232,139	-8,535,800	717,811	-3,328,449	6,482,539
X	Profit/ (Loss) from discontinued operations						
XI	Tax expense of discontinued operations	-	-	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)						
XIII	Profit/Loss for the period (IX+XII)	217,567	232,139	-8,535,800	717,811	-3,328,449	6,482,539
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	217,567	232,139	-8,535,800	717,811	-3,328,449	6,482,539
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500
XVII	Earning Per Equity Share (for continuing operation):						
	1) Basic	0.07	0.08	-2.79	0.24	-1.09	2.12
	2) Diluted	0.07	0.08	-2.79	0.24	-1.09	2.12
XVIII	Earning Per Equity Share (for discontinued operation):						
	1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):						
	1) Basic	0.07	0.08	-2.79	0.24	-1.09	2.12
	2) Diluted	0.07	0.08	-2.79	0.24	-1.09	2.12

Notes:

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on 14th February, 2024. The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.
- Company's Business activity falls within a single business segment i.e. Horticulture in terms of Ind-AS 108 on Segment Reporting.
- Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited



Yogesh Agrawal
 Yogesh Agrawal
 (Chairman & Managing Director)
 DIN-01165288
 Add: G-74 Pushkar Enclave
 Paschim Vihar, New Delhi-110063

Place : Delhi
 Dated : 14.02.2024

ANDROS & CO.
CHARTERED ACCOUNTANTS

901, TOWER-1, PEARL OMAXE, PLOT B-1,
NETAJI SHUBHASH PLACE, PITAMPURA
DELHI-110034
Ph-011-47060901
Email: cabhavukgarg@gmail.com

LIMITED REVIEW REPORT

To,
The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheri,
Tehsil- Bahadurgarh, District-Jhajjar, Haryana-124507.

**Subject: Limited Review Report on the Un-Audited Financial Results for the Quarter ended on
December 31, 2023 and year to date from April 01, 2023 to December 31, 2023**

We have reviewed the accompanying statement of unaudited financial results for the Quarter ended on December 31, 2023 and year to date from April 01, 2023 to December 31, 2023 ('the statement') of Genomic Valley Biotech Limited ('the Company') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement has been prepared by the Company's Management in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards, prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ANDROS & CO.
Chartered Accountants
FRN :0008976N



Bhavuk Garg
CA Bhavuk Garg) (Partnership Firm)
(Membership No.-502310)

Place: Delhi
Date: 14-02-2024
UDIN: 24502310-BJZYHE-9387